10.6084/m9.figshare.11313890.v1 Rodrigo Egidio da Silva Rodrigo Egidio da Silva Juliana de Lima Jácomo Juliana de Lima Jácomo Lara Ribeiro Vilela Lara Ribeiro Vilela Antônio Wilson Soares de Oliveira Antônio Wilson Soares de Oliveira Francisco Wellington Rodrigues Francisco Wellington Rodrigues Profile and variability of intraocular pressure after the EX-PRESS device implant SciELO journals 2019 Glaucoma drainage implants Glaucoma Intraocular pressure Drug therapy Postoperative complications Prosthesis implantation/methods 2019-12-04 02:51:48 Dataset https://scielo.figshare.com/articles/dataset/Profile_and_variability_of_intraocular_pressure_after_the_EX-PRESS_device_implant/11313890 <div><p>Abstract Objective: The EX-PRESS device is a surgical alternative for the treatment of POAG. To describe the IOP behavior before and after the implantation of the EX-PRESS, the pharmacological treatment used in the pre and postoperative period and the complications in the first year of the postoperative period. Methods: A quantitative descriptive study with review of electronic medical records of a private ophthalmological reference hospital in Goiânia (GO) from 2013 to 2018. Sample composed of 8 eyes with POAG subjected to the EX-PRESS implant. We observed the variables: gender, age, operated eye, antiglaucomatous medications used, pre and postoperative intraocular pressure, and possible complications. Results: In the preoperative period, all eyes used antiglaucomatous drops, 75% used 3 or more different classes simultaneously. After 12 months of EX-PRESS, only 12.5% used three or more eye drops and 37.5% did not use any eye drops. On average, IOP varied from 18.63mmHg (SD 9.38) in the preoperative period to 14.50mmHg (SD 4.14) at 12 months postoperatively. Complications were: ocular hypotension, ocular hypertension; thinning of the conjunctival blister, cystic blister obstruction of the EX-PRESS. We resolved all coplications. Conclusion: The efficacy of EX-PRESS in IOP reduction was verified in the study. Concomitantly, there was a considerable decrease in anti-glaucomatous medications, and few associated complications.</p></div>